Clinical Study

Effectiveness of a Nurse-Managed Protocol to Prevent Hypoglycemia in Hospitalized Patients with Diabetes

Table 1

Patients’ main characteristics.

Phase A (84 patients)Phase B (266 patients)

Age (years) mean ± SD70.2 ± 10.170.9 ± 11.00.396
 <65 (no., %)21 (25.0)69 (25.9)0.173
 65–74 (no., %)34 (40.5)80 (30.1)
 ≥75 (no., %)29 (34.5)117 (44.0)
Male (number, %)60 (71.4)168 (63.2)0.166
History of diabetes (number, %)
 (i) None4 (4.8)18 (6.7)0.076
 (ii) Type 1 3 (3.5)12 (4.5)
 (iii) Type 2 75 (89.3)236 (88.8)
 (iv) Other types2 (2.4)0 (0.0)
Glucose-lowering drugs used at home (number, %)
 (i) None7 (8.3)29 (10.9)0.499
 (ii) Oral53 (63.1)149 (56.0)
 (iii) Insulin22 (26.2)74 (27.8)
 (iv) Insulin and oral drugs2 (2.4)14 (5.3)
History of malignant cancer (number, %)9 (10.7)31 (12.0)0.805
Body mass index (kg/m2)
 <18 (number, %)0 (0.0)2 (0.8)<0.001
 18–24 (number, %)18 (21.4)87 (32.7)
 25–29 (number, %)39 (46.4)118 (44.4)
 ≥30 (number, %)27 (32.1)58 (21.8)
Blood glucose at admission (mg/dL)
 <200 (number, %)53 (63.1)174 (65.4)0.895
 ≥200 (number, %)31 (36.9)91 (34.2)
HbA1c at admission (mmol/mol, %)
 <6 (no., %)4 (4.8)33 (12.4)0.989
 6–6.9 (no., %)31 (36.9)83 (31.2)
 7–7.9 (no., %)25 (29.8)54 (20.3)
 ≥8 (no., %)24 (28.6)92 (35.6)
eGFR at hospital admission (mL/min/1.73 m2)
 ≥9017 (20.2)50 (18.8)0.944
 60–8927 (32.1)95 (35.7)
 30–5930 (35.7)92 (34.6)
 <3010 (11.9)29 (10.9)
Liver failure (number, %)2 (2.4)5 (2.3)0.778
Infection in hospital (number, %)17 (20.2)59 (22.2)0.707
Initial s.c. insulin dose (IU/kg/day)
0.657 (67.9)200 (75.2)0.168
0.627 (32.1)65 (24.4)
Diagnosis at discharge (number, %)
 (i) STEMI21 (25.0)94 (35.3)0.0760
 (ii) NSTEMI44 (52.4)111 (41.7)
 (iii) Unstable angina3 (3.6)23 (8.7)
 (iv) Other16 (19.0)38 (14.3)

SD = standard deviation; STEMI = ST-segment elevation acute myocardial infarction; NSTEMI = non-ST-segment elevation acute myocardial infarction; eGFR = estimated glomerular filtration rate calculated according to CKD-EPI formula.